Faron Pharmaceuticals Oy Working Capital to Net Assets Ratio
Faron Pharmaceuticals Oy working capital to net assets ratio. Faron Pharmaceuticals Oy (FARN) has a Working Capital to Net Assets ratio of -43.0% as of June 2025. Working capital of GBX6.98 Million (current assets of GBX14.80 Million minus current liabilities of GBX7.83 Million) is measured against net assets of GBX-16.25 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Faron Pharmaceuticals Oy (FARN) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Faron Pharmaceuticals Oy (2012–2024)
Working capital to net assets ratio of Faron Pharmaceuticals Oy from 2012 to 2024. This chart shows how Faron Pharmaceuticals Oy's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of June 2025, the ratio stands at -43.0%, reflecting working capital of GBX6.98 Million against net assets of GBX-16.25 Million GBX. See Faron Pharmaceuticals Oy liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Faron Pharmaceuticals Oy Working Capital to Net Assets Ratio by Year (2012–2024)
Faron Pharmaceuticals Oy working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Faron Pharmaceuticals Oy from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Faron Pharmaceuticals Oy.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -9.2% | GBX894.00K | GBX-9.76 Million | GBX11.06 Million | GBX10.17 Million | ▼ -49.7 pp |
| 2023 | 40.5% | GBX-6.14 Million | GBX-15.16 Million | GBX8.87 Million | GBX15.01 Million | ▲ +34.1 pp |
| 2022 | 6.5% | GBX-741.00K | GBX-11.48 Million | GBX9.73 Million | GBX10.47 Million | ▼ -159.6 pp |
| 2021 | 166.0% | GBX4.84 Million | GBX2.92 Million | GBX12.02 Million | GBX7.18 Million | ▲ +213.0 pp |
| 2020 | -46.9% | GBX868.00K | GBX-1.85 Million | GBX7.37 Million | GBX6.50 Million | ▼ -241.3 pp |
| 2019 | 194.3% | GBX3.13 Million | GBX1.61 Million | GBX9.20 Million | GBX6.08 Million | ▼ -98.3 pp |
| 2018 | 292.7% | GBX1.08 Million | GBX369.00K | GBX6.83 Million | GBX5.75 Million | ▲ +183.6 pp |
| 2017 | 109.1% | GBX5.17 Million | GBX4.74 Million | GBX13.23 Million | GBX8.06 Million | ▼ -0.8 pp |
| 2016 | 109.9% | GBX11.96 Million | GBX10.88 Million | GBX16.33 Million | GBX4.37 Million | ▲ +6.2 pp |
| 2015 | 103.7% | GBX11.59 Million | GBX11.18 Million | GBX13.79 Million | GBX2.20 Million | ▲ +46.4 pp |
| 2014 | 57.3% | GBX-681.00K | GBX-1.19 Million | GBX981.00K | GBX1.66 Million | ▼ -5.6 pp |
| 2013 | 62.9% | GBX-597.00K | GBX-949.00K | GBX1.14 Million | GBX1.74 Million | ▲ +51.9 pp |
| 2012 | 11.0% | GBX-92.00K | GBX-837.00K | GBX860.00K | GBX952.00K | — |